Delving into the Latest Updates on Biota Scientific Management Pty Ltd. with Synapse

Overview

The primary aim of this Phase 1 study is to evaluate the effect of vapendavir daily doses of 528 mg daily (QD) and 264 mg twice daily (BID) on the pharmacokinetic (PK) profile of midazolam, a cytochrome (CYP) 3A4 substrate. Additionally, the effect of midazolam on the PK profile of vapendavir, a PK profile comparison of vapendavir in males and females, as well as the safety of vapendavir will also be assessed.

Start Date01 May 2014

Sponsor / Collaborator

Biota Scientific Management Pty Ltd.

NCT02014649 / TerminatedPhase 1/2

Randomised, Parallel Dose, Phase 1/2 Safety and Pharmacokinetics Study of Inhaled Laninamivir Octanoate TwinCaps® Dry Powder Inhaler in Children With Naturally Acquired Influenza A or B

This Phase 1/2 protocol is designed to collect safety, tolerability and pharmacokinetic data of two doses of Laninamivir Octanoate in children and adolescents. The protocol will also explore virology and efficacy endpoints.

Start Date01 Nov 2013

Sponsor / Collaborator

Biota Scientific Management Pty Ltd.

[+1]

NCT02022761 / CompletedPhase 1

A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Inhaled Laninamivir Octanoate in Adults With Chronic Asthma

This is a single centre, randomized, double-blind, placebo-controlled, single ascending dose study, in which the safety and pharmacokinetics of laninamivir octanoate administered by inhalation via the TwinCaps® DPI will be assessed in adults with mild or moderate chronic asthma.

Start Date01 Oct 2013

Sponsor / Collaborator

Biota Scientific Management Pty Ltd.

[+1]

100 Clinical Results associated with Biota Scientific Management Pty Ltd.

Login to view more data

0 Patents (Medical) associated with Biota Scientific Management Pty Ltd.

Login to view more data

9

Literatures (Medical) associated with Biota Scientific Management Pty Ltd.

01 May 2016·ChemInform

ChemInform Abstract: A Second‐Generation Chemoenzymatic Total Synthesis of Platencin.

Author: Anthony C. Willis ; Rehmani N. Muhammad ; Martin G. Banwell ; Alistair G. Draffan

A total synthesis of the potent antibacterial agent platencin is described. The reaction sequence used involves, as starting material, an enantiomerically pure cis-1,2-dihydrocatechol derived from the whole-cell biotransformation of iodobenzene. Simple chemical manipulations of this metabolite provide a triene that engages in a thermally promoted intramolecular Diels–Alder reaction to establish the octahydro-2H-2,4a-ethanonaphthalene core of platencin.

01 Feb 2015·Bioorganic & Medicinal Chemistry LettersQ4 · MEDICINE

Prodrugs of imidazotriazine and pyrrolotriazine C-nucleosides can increase anti-HCV activity and enhance nucleotide triphosphate concentrations in vitro

Q4 · MEDICINE

Article

Author: Bond, Silas ; Porter, Kate ; Frey, Barbara ; Jahangiri, Saba ; Tyndall, Edward M ; Pool, Brett ; Halim, Rosliana ; Thomas, Jesse ; Tucker, Simon P ; Luttick, Angela ; Wirth, Veronika ; Tilmanis, Danielle ; Draffan, Alistair G

A number of prodrugs of HCV-active purine nucleoside analogues 2'-C-methyl 4-aza-9-deaza adenosine 1, 2'-C-methyl 4-aza-7,9-dideaza adenosine 2, 2'-C-methyl 4-aza-9-deaza guanosine 3 and 2'-C-methyl 4-aza-7,9-dideaza guanosine 4 were prepared and evaluated to improve potency, selectivity and liver targeting. Phosphoramidate guanosine prodrugs (3a-3k and 4a, b) showed insufficient cell activity for further profiling. Striking enhancement in replicon activity relative to the parent was observed for phosphoramidate imidazo[2,1-f][1,2,4]triazine-4-amine adenosine prodrugs (1a-1p), but this was accompanied by an increase in cytotoxicity. Improved or similar potency without a concomitant increase in toxicity relative to the parent was demonstrated for phosphoramidate pyrrolo[2,1-f][1,2,4]triazine-4-amine adenosine prodrugs (2a-2k). Carbamate, ester and mixed prodrugs of 2 showed mixed results. Selected prodrugs of 2 were analysed for activation to the triphosphate, with most demonstrating much better activation in hepatocytes over replicon cells. The best activation was observed for a mixed phosphoramidate-3'ester (11) followed by a simple 3'-ester (10).

01 Feb 2015·Bioorganic & Medicinal Chemistry LettersQ4 · MEDICINE

1,2,3,9b-Tetrahydro-5H-imidazo[2,1-a]isoindol-5-ones as a new class of respiratory syncytial virus (RSV) fusion inhibitors. Part 2: Identification of BTA9881 as a preclinical candidate

Q4 · MEDICINE

Article

Author: Tucker, Simon P ; Draffan, Alistair G ; Lambert, John ; Morton, Craig J ; Fenner, Jennifer E ; Lin, Bo ; Anderson, Kelly H ; Bond, Silas ; Sanford, Vanessa ; Lim, Chin Yu ; Mayes, Penelope A ; Nearn, Roland H ; Luttick, Angela ; Mitchell, Jeffrey P

Respiratory syncytial virus (RSV) is a major cause of respiratory tract infections in infants, young children and adults. 1,2,3,9b-Tetrahydro-5H-imidazo[2,1-a]isoindol-5-ones with general structure 1 were previously identified as promising inhibitors of RSV targeting the fusion glycoprotein. In particular, the introduction of a nitrogen at the 8-position of the tricyclic core yielded lead compounds 2 and 3. Extensive exploration of the R(2) group established that certain heterocyclic amides conferred potent RSV A&B activity and a good balance of physicochemical and pharmacokinetic properties. The antiviral activity was found to reside in a single enantiomer and compound 33a, (9bS)-9b-(4-chlorophenyl)-1-(pyridin-3-ylcarbonyl)-1,2,3,9b-tetrahydro-5H-imidazo[1',2':1,2]pyrrolo[3,4-c]pyridin-5-one (known as BTA9881), was identified as a candidate for preclinical development.

100 Deals associated with Biota Scientific Management Pty Ltd.

Login to view more data

100 Translational Medicine associated with Biota Scientific Management Pty Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 07 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Other

4

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Vapendavir ( HRV capsid )	Rhinovirus infection More	Pending
Laninamivir Octanoate Hydrate ( neuraminidase )	Influenza B virus infection More	Pending
Anti-HCV agents(Biota Scientific Management/Boehringer Ingelheim Ltd)	Hepatitis C More	Pending
BTA-9881 ( RSV F protein )	Respiratory Syncytial Virus Infections More	Pending